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Abstracts / Biol Blood Marrow Transplant 19 (2013) S178eS193 S183days vs. 13.1 days, P < 0.001) in the ID-CY pts, likely because
of higher infused CD34+ cell dose. Rate of adverse events
were higher in the ID-CY cohort including neutropenic fevers
(p¼0.02), intravenous antibiotic use (p¼0.03), hospitaliza-
tion (p¼0.05) and packed red cell transfusions (p¼0.007).
Conclusion: In the era of novel agents compared to P, ID-CY
produced a more robust PBPC mobilization, faster engraft-
ment, but was associated with signiﬁcantly higher (but
manageable) toxicity, and no difference in mobilization
failure rates. These data support use of either intermediate
dose - cyclophosphamide or plerixafor-based PBPC mobili-
zation in MM pts undergoing stem cell collection following
novel induction therapies.Figure 1. Log-HCMI decay curve: (A) Representative NHL patient from cluster
1; (B) Representative MM patient from cluster 2; (C) Representative NHL
patient from cluster 3.137
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Hematopoietic cell (HC) mobilization to support high dose
therapy is generally carried out using cytokines with or
without chemotherapy. The resulting HC yield and the
duration of cell collection have beenwell studied and tend to
be variable. No consistent unifying relationship has been
described which would reliably represent the kinetics of this
process between different patients. To accomplish this, the
HC yield from the mobilization procedures for 431 patients
was examined. The diagnoses were multiple myeloma
(N¼220), non-Hodgkin's lymphoma (155) and Hodgkin's
lymphoma (56). Mobilizing regimens included chemo-
therapy + GCSF (97), GCSF (232), GCSF + plerixafor (84). To
normalize the HC yield between patients, the total number of
CD34+ cells collected on a given day was divided by the
volume of blood (L) processed and was termed the HC
mobilization index (HCMI). For the combined cohort the
mean HCMI value on day 1 of apheresis (HCMI1) was 19.7
( 38.9)  106 CD34+ cells/L/day. A signiﬁcant correlation
was found between HCMI1 and the circulating CD34+ cell
count on day 1 (R2 0.69, P < 0.01), and the total HC yield in
each patient (0.97, P < 0.01). These observations were
consistent in patients with various diagnoses and receiving
different mobilizing regimens. Daily HCMI values were
plotted over days of apheresis to determine the rate of
change. A general trend of declining HCMI values over days
of apheresis was observed, with some patients showing an
initial increase. To offset the effect of the large range of HCMI
values observed, the logarithm (log) of HCMI for each day
was plotted against day of apheresis for each patient with>2
days of collection (n¼279) to give individual log-HCMI decay
curves. A quadratic equation (y¼ax2+bx+c) provided the best
ﬁt for these curves (mean R2 0.88), demonstrating a parabolic
relationship such that log HCMI increased and declined in
proportion to square of time (in days) following the start of
apheresis. It was noted that the values of coefﬁcients were
normally distributed in the study population; coefﬁcient
a (mean, -0.04  0.2), b (0.04  1.1), and c (1.7  1.2). A Two-
step cluster analysis of these coefﬁcients distinguished three
main groups (clusters) of patients. Patients in cluster 1 (38%)
tended to have an initial increase in HCMI followed by an
asymptotic decline; those in clusters 2 (50.2%) and 3 (8.6%)
displayed declines of varying magnitude. Cluster 1 showed
a higher proportion of NHL patients (p¼0.01), whereas MM
was over-represented in cluster 2 (p¼0.008), consistent withthe notion that prior chemotherapy received by NHL patients
impacted their mobilization kinetics. In conclusion, we
demonstrate that HC yield during various mobilization
procedures follows mathematically predictable kinetics
which may reﬂect underlying hematopoietic reserve.138
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Background: High-dose chemotherapy and autologous
hematopoietic stem cell transplantation (auto-HCT) is an
effective treatment for systemic light chain amyloidosis (AL).
Fluid retention and weight gain during peripheral blood
hematopoietic stem cell (PBSC) mobilization with growth
